Labcorp Holdings Inc.
LH
Get informed when a big investor buys or sells
+ FollowMarket Cap$26.77B
Close$
Earnings Call Q2 2026
July 30, 2026 - AI Summary
Solid Q2 results; margins & EPS up strongly
- Revenue +6% to $3.7B; organic revenue +4.2%
- Adjusted operating margin +70 bps to 15.8%
- Adjusted EPS +15% to $4.99
- Free cash flow $314M (notably down vs prior year due to working capital timing and planned capex increases)
Diagnostics growth driven by specialty + higher tests per accession
- Diagnostics revenue +$5.5% to $2.9B
- Organic Diagnostics +3.6%, with volume +3% and price/mix +2.5%
- Management emphasized continued specialty testing outgrowing routine testing and ongoing increases in “tests per accession” (supporting mix/price and volume momentum)
- Also said ACA/Medicaid impact is not a big drag overall (details below)
BLS strong quarter; Early Development restructuring now largely “behind”
- Biopharma Laboratory Services revenue +$6.5% to $836M
- Book-to-bill: 1.14 (quarter) / 1.03 (TTM)—positive demand signal
- Central Labs (majority of BLS) performing strongly: Central Labs +10% (reported) / ~+8% (organic constant currency)
- Early Development: -1% reported, but +3% organic constant currency; benefits and margin expansion tied to strategic actions that are announced and largely complete
Exclusive for Stockcircle Pro members
Sign up
$340.64
3.6% upside
Current Fair Value
3.6% upsideUndervalued by 3.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $26.77 Billion |
|---|---|
| Enterprise Value | $33.78 Billion |
| Dividend Yield | $2.88 (0.88%) |
| Earnings per Share | $10.54 |
| Beta | 0.85 |
| Outstanding Shares | 81,700,000 |
Return
| Return on Equity | 11.65% |
|---|---|
| Return on Assets | 5.41% |
| Return on Invested Capital | 9.78% |
Valuation & Multiples
| P/E Ratio | 27.03 |
|---|---|
| PEG | 105.76 |
| Price to Sales | 1.88 |
| Price to Book Ratio | 3.13 |
| Enterprise Value to Revenue | 2.35 |
| Enterprise Value to EBIT | 21.06 |
| Enterprise Value to Net Income | 33 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | 0.83 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$4.78
Average shareholder expectationRevenue Estimate
$3.71 B
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
$4.65
Average shareholder expectationRevenue Estimate
$3.76 B
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 158.99% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.08%▼ 94.10% |
|---|---|
| Total Invested | $765.10M▼ 96.58% |
| Investors Holding | 253▼ 818.00% |
ESG Score
No data
About Laboratory Corp. Of America Holdings
71,000 employees
CEO: David King Labcorp Holdings, Inc. delivers specialized diagnostic laboratory services. Its purpose is to empower a diverse group of stakeholders – including medical professionals, hospitals, pharmaceutical companies, scientific researchers, and ind...